These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

107 related items for PubMed ID: 18815425

  • 1. Immunohistochemical localisation of intravitreally injected bevacizumab at the posterior pole of the primate eye: implication for the treatment of retinal vein occlusion.
    Julien S, Heiduschka P, Hofmeister S, Schraermeyer U.
    Br J Ophthalmol; 2008 Oct; 92(10):1424-8. PubMed ID: 18815425
    [Abstract] [Full Text] [Related]

  • 2. Immunohistochemical localisation of intravitreally injected bevacizumab in the anterior chamber angle, iris and ciliary body of the primate eye.
    Peters S, Heiduschka P, Julien S, Bartz-Schmidt KU, Schraermeyer U.
    Br J Ophthalmol; 2008 Apr; 92(4):541-4. PubMed ID: 18211933
    [Abstract] [Full Text] [Related]

  • 3. Retinal sensitivity after intravitreal injection of bevacizumab for the treatment of macular edema secondary to retinal vein occlusion.
    Yamaike N, Tsujikawa A, Sakamoto A, Ota M, Kotera Y, Miyamoto K, Kita M, Yoshimura N.
    Retina; 2009 Jun; 29(6):757-67. PubMed ID: 19289982
    [Abstract] [Full Text] [Related]

  • 4. Early intravitreal bevacizumab for non-ischaemic central retinal vein occlusion.
    Rensch F, Jonas JB, Spandau UH.
    Acta Ophthalmol; 2009 Feb; 87(1):77-81. PubMed ID: 18937800
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Comparison of two doses of intravitreal bevacizumab as primary treatment for macular edema secondary to branch retinal vein occlusions: results of the Pan American Collaborative Retina Study Group at 24 months.
    Wu L, Arevalo JF, Berrocal MH, Maia M, Roca JA, Morales-Cantón V, Alezzandrini AA, Díaz-Llopis MJ.
    Retina; 2009 Feb; 29(10):1396-403. PubMed ID: 19898177
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Rebound of macular edema after intravitreal bevacizumab therapy in eyes with macular edema secondary to branch retinal vein occlusion.
    Yasuda S, Kondo M, Kachi S, Ito Y, Terui T, Ueno S, Terasaki H.
    Retina; 2011 Jun; 31(6):1075-82. PubMed ID: 21478810
    [Abstract] [Full Text] [Related]

  • 10. Bevacizumab compared with macular laser grid photocoagulation for cystoid macular edema in branch retinal vein occlusion.
    Russo V, Barone A, Conte E, Prascina F, Stella A, Noci ND.
    Retina; 2009 Apr; 29(4):511-5. PubMed ID: 19174717
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Effect of intravitreal anti-vascular endothelial growth factor treatment on the retinal gene expression in acute experimental central retinal vein occlusion.
    Drechsler F, Köferl P, Hollborn M, Wiedemann P, Bringmann A, Kohen L, Rehak M.
    Ophthalmic Res; 2012 Apr; 47(3):157-62. PubMed ID: 22116547
    [Abstract] [Full Text] [Related]

  • 13. Effects of apelin and vascular endothelial growth factor on central retinal vein occlusion in monkey eyes intravitreally injected with bevacizumab: a preliminary study.
    Zhao T, Lu Q, Tao Y, Liang XY, Wang K, Jiang YR.
    Mol Vis; 2011 Apr 27; 17():1044-55. PubMed ID: 21552499
    [Abstract] [Full Text] [Related]

  • 14. Comparison of two doses of intravitreal bevacizumab (Avastin) for treatment of macular edema secondary to branch retinal vein occlusion: results from the Pan-American Collaborative Retina Study Group at 6 months of follow-up.
    Wu L, Arevalo JF, Roca JA, Maia M, Berrocal MH, Rodriguez FJ, Evans T, Costa RA, Cardillo J, Pan-American Collaborative Retina Study Group (PACORES).
    Retina; 2008 Feb 27; 28(2):212-9. PubMed ID: 18301025
    [Abstract] [Full Text] [Related]

  • 15. Long-term effect of intravitreal bevacizumab (avastin) in patients with chronic diffuse diabetic macular edema.
    Kook D, Wolf A, Kreutzer T, Neubauer A, Strauss R, Ulbig M, Kampik A, Haritoglou C.
    Retina; 2008 Oct 27; 28(8):1053-60. PubMed ID: 18779710
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Intravitreal bevacizumab (avastin) for central and hemicentral retinal vein occlusions: IBeVO study.
    Costa RA, Jorge R, Calucci D, Melo LA, Cardillo JA, Scott IU.
    Retina; 2007 Feb 27; 27(2):141-9. PubMed ID: 17290194
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Intravitreal bevacizumab versus triamcinolone acetonide for macular edema due to branch retinal vein occlusion: a matched study.
    Hou J, Tao Y, Jiang YR, Li XX, Gao L.
    Chin Med J (Engl); 2009 Nov 20; 122(22):2695-9. PubMed ID: 19951598
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.